Increased CCL18 expression in patients with cutaneous T-cell lymphoma: Association with disease severity and prognosis

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 1, 2013, Pages

  Miyagaki, T ^a   Sugaya, M ^a   Suga, H ^a   Ohmatsu, H ^a   Fujita, H ^a   Asano, Y ^a   Tada, Y ^a   Kadono, T ^a   Sato, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CCL18 CHEMOKINE; CHEMOKINE; EOTAXIN 3; INTERLEUKIN 10; INTERLEUKIN 31; INTERLEUKIN 4; LACTATE DEHYDROGENASE; MESSENGER RNA; SOLUBLE INTERLEUKIN 2 RECEPTOR; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CUTANEOUS T CELL LYMPHOMA; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; UPREGULATION;

ADULT; AGED; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; CHEMOKINES, CC; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE VALUES; RNA, MESSENGER; SKIN NEOPLASMS; STATISTICS, NONPARAMETRIC; UP-REGULATION;

EID: 84872840027     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04495.x     Document Type: Article

References (54)

1. Hieshima K, Imai T, Baba M, et al. A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. J Immunol 1997; 159: 1140-1149.
2. Wells TN, Peitsch MC,. The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and expressed sequence tag databases. J Leukoc Biol 1997; 64: 545-550.
3. Adema GJ, Hartgers F, Verstraten R, et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 1997; 387: 713-717.
4. Kodelja V, Müller C, Politz O, et al. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 1998; 160: 1411-1418.
5. Schutyser E, Richmond A, Van Damme J,. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol 2005; 78: 14-26.
6. Schraufstatter I, Takamori H, Sikora L, et al. Eosinophils and monocytes produce pulmonary and activation-regulated chemokine, which activates cultured monocytes/macrophages. Am J Physiol Lung Cell Mol Physiol 2004; 286: L494-L501.
7. Sallusto F, Palermo B, Lenig D, et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999; 29: 1617-1625.
8. Song E, Ouyang N, Hörbelt M, et al. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol 2000; 204: 19-28.
9. Pivarcsi A, Gombert M, Dieu-Nosjean MC, et al. CC chemokine ligand 18, an atopic dermatitis-associated and dendritic cell-derived chemokine, is regulated by staphylococcal products and allergen exposure. J Immunol 2004; 173: 5810-5817.
10. Günther C, Bello-Fernandez C, Kopp T, et al. CCL18 is expressed in atopic dermatitis and mediates skin homing of human memory T cells. J Immunol 2005; 174: 1723-1728.
11. Lindhout E, Vissers JL, Hartgers FC, et al. The dendritic cell-specific CC-chemokine DC-CK1 is expressed by germinal center dendritic cells and attracts CD38-negative mantle zone B lymphocytes. J Immunol 2001; 166: 3284-3289.
12. Vulcano M, Struyf S, Scapini P, et al. Unique regulation of CCL18 production by maturing dendritic cells. J Immunol 2003; 170: 3843-3849.
13. Goebeler M, Trautmann A, Voss A, et al. Differential and sequential expression of multiple chemokines during elicitation of allergic contact hypersensitivity. Am J Pathol 2001; 158: 431-440.
14. Nomura I, Gao B, Boguniewicz M, et al. Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. J Allergy Clin Immunol 2003; 112: 1195-1202.
15. Park CO, Lee HJ, Lee JH, et al. Increased expression of CC chemokine ligand 18 in extrinsic atopic dermatitis patients. Exp Dermatol 2008; 17: 24-29.
16. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol 2007; 119: 1210-1217.
17. Hon KL, Ching GK, Ng PC, Leung TF,. Exploring CCL18, eczema severity and atopy. Pediatr Allergy Immunol 2011; 22: 704-707.
18. Kwon YS, Oh SH, Wu WH, et al. CC chemokines as potential immunologic markers correlated with clinical improvement of atopic dermatitis patients by immunotherapy. Exp Dermatol 2010; 19: 246-251.
19. Günther C, Carballido-Perrig N, Kopp T, et al. CCL18 is expressed in patients with bullous pemphigoid and parallels disease course. Br J Dermatol 2009; 160: 747-755.
20. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
21. Girardi M, Heald PW, Wilson LD,. The pathogenesis of mycosis fungoides. N Eng J Med 2004; 350: 1978-1988.
22. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115: 798-812.
23. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46: 95-106.
24. Rajka G, Winkelmann RK,. Atopic dermatitis and Sézary syndrome. Arch Dermatol 1984; 120: 83-84.
25. Bushkell LL, Jordon RE,. Bullous pemphigoid: a cause of peripheral blood eosinophilia. J Am Acad Dermatol 1983; 8: 648-651.
26. Kakinuma T, Sugaya M, Nakamura K, et al. Thymus and activation-regulated chemokine (TARC) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003; 48: 23-30.
27. Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001; 107: 535-541.
28. Kakinuma T, Wakugawa M, Nakamura K, et al. High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid. Br J Dermatol 2003; 148: 203-210.
29. Miyagaki T, Sugaya M, Fujita H, et al. Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Invest Dermatol 2010; 130: 2304-2311.
30. Kaburagi Y, Shimada Y, Nagaoka T, et al. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1alpha, MIP-1beta, and eotaxin) in patients with atopic dermatitis. Arch Dermatol Res 2001; 293: 350-355.
31. Frezzolini A, Teofoli P, Cianchini G, et al. Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid. Eur J Dermatol 2002; 12: 27-31.
32. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC Press, Lyon, 2008.
33. Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29: 2598-2607.
34. Sugaya M, Fang L, Cardones AR, et al. Oncostatin M enhances CCL21 expression by microvascular endothelial cells and increases the efficiency of dendritic cell trafficking to lymph nodes. J Immunol 2006; 177: 7665-7672.
35. Günther C, Zimmermann N, Berndt N, et al. Up-regulation of the chemokine CCL18 by macrophages is a potential immunomodulatory pathway in cutaneous T-cell lymphoma. Am J Pathol 2011; 179: 1434-1442.
36. Martí RM, Estrach T, Reverter JC, Mascarõ JM,. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991; 127: 1511-1516.
37. Wasik MA, Vonderheid EC, Bigler RD, et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 1996; 132: 42-47.
38. van Lieshout AW, Vonk MC, Bredie SJ, et al. Enhanced interleukin-10 production by dendritic cells upon stimulation with Toll-like receptor 4 agonists in systemic sclerosis that is possibly implicated in CCL18 secretion. Scand J Rheumatol 2009; 38: 282-290.
39. Cheung PF, Wong CK, Ho AW, et al. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol 2010; 22: 453-467.
40. Kagami S, Sugaya M, Minatani Y, et al. Elevated serum CTACK/CCL27 levels in CTCL. J Invest Dermatol 2006; 126: 1189-1191.
41. Papadavid E, Economidou J, Psarra A, et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome. Br J Dermatol 2003; 148: 709-718.
42. Vowels BR, Cassin M, Vonderheid EC, Rook AH,. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99: 90-94.
43. Lewis CE, Pollard JW,. Distinct role of macrophages in different tumour microenvironments. Cancer Res 2006; 66: 605-612.
44. Hasselblom S, Hansson U, Sigurdardottir M, et al. Expression of CD68 + tumour-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int 2008; 58: 529-532.
45. Steidl C, Lee T, Shah SP, et al. Tumour-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362: 875-885.
46. Zhang W, Wang L, Zhou D, et al. Expression of tumour-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk Lymphoma 2011; 52: 46-52.
47. Chen J, Yao Y, Gong C, et al. CCL18 from tumour-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011; 19: 541-555.
48. Berger CL, Hanlon D, Kanada D, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 2002; 99: 2929-2939.
49. Schlapbach C, Ochsenbein A, Kaelin U, et al. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma. J Am Acad Dermatol 2010; 62: 995-1004.
50. Goteri G, Filosa A, Mannello B, et al. Density of neoplastic lymphoid infiltrate, CD8+ T cells, and CD1a+ dendritic cells in mycosis fungoides. J Clin Pathol 2003; 56: 453-458.
51. Rowden G, Phillips TM, Lewis MG, Wilkinson RD,. Target role of Langerhans cells in mycosis fungoides: transmission and immuno-electron microscopic studies. J Cutan Pathol 1979; 6: 364-382.
52. Duvic M, Sherman ML, Wood GS, et al. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 2006; 55: 807-13.
53. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-3115.
54. Kaplan EH, Rosen ST, Norris DB, et al. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990; 82: 208-212.